Med24
overweight-obesity 1. 10. 2026 • 2 min read • Clinical obesity

Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index

Lipoedema is a painful adipose tissue disorder marked by disproportionate limb fat and often misclassified as generalized obesity or lymphoedema. This review examines its metabolic phenotype and implications for cardiometabolic assessment and management. PubMed/MEDLINE was searched from inception through May 2026 for...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Lipoedema is characterized by disproportionate limb fat, frequently misidentified as obesity or lymphoedema. A review examined the metabolic phenotype of lipoedema and its implications for cardiometabolic assessment. The search encompassed studies on lipoedema, obesity, body composition, metabolic risk, insulin resistance, diabetes, lifestyle interventions, pharmacotherapy, and liposuction, utilizing PubMed/MEDLINE data from its inception through May 2026.

Metabolic Phenotype and Risk Assessment

Observations indicate that women with lipoedema may exhibit fewer metabolic abnormalities compared to women with BMI-matched lifestyle-related overweight or obesity. However, this does not establish metabolic protection. Differences may be attributed to variations in central adiposity, disease stage, diagnostic criteria, body composition, inflammation, or referral patterns. Obesity and glucose-lowering therapies remain appropriate for established indications. Direct modification of lipoedema has not been demonstrated. Cardiometabolic risk assessment in lipoedema requires a phenotype-based approach, differentiating painful limb adiposity from central and ectopic fat. This approach should incorporate factors such as age, sex, menopausal status, and established risk factors.

Sponsored content

Future Research Directions

Further research, including prospective studies with standardized criteria and direct measures of insulin sensitivity, is needed to clarify long-term risk and to differentiate lipoedema biology from coexisting central obesity.

Original Scientific Source
Clinical obesity
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement